India's humanoid robots library · Specs, prices, news and buying guides - no hype.
RobotWale
Applications Rehab Exoskeletons Hands-on coverage

Rehab Exoskeletons: Shipping Hardware, Clinical Evidence, and the Indian Market

📅 Published ⏰ 10 min read 👤 By RobotWale Editors
A therapist assists a man with a prosthetic leg during a rehabilitation session indoors.
Summary A grounded assessment of the commercial rehab exoskeleton sector, evaluating ReWalk, Ekso Bionics, and Cyberdyne HAL against verified clinical outcomes, shipping status, and India market accessibility.

The Commercial Reality of Rehab Exoskeletons

Rehabilitation exoskeletons occupy a distinct space in assistive robotics: they are regulated medical devices, not consumer gadgets, and their value proposition must be measured by shipping hardware, verified clinical deployments, and peer-reviewed outcomes rather than prototype demonstrations. The sector has matured past the era of rendered concepts and funding announcements. Today, three platforms dominate the clinical landscape: ReWalk Robotics, Ekso Bionics, and Cyberdyne's HAL system. Each has navigated distinct regulatory pathways, adopted different actuation architectures, and established varying deployment models across hospital and outpatient settings.

This assessment grades these systems by shipping hardware first, pilot deployments second, and public announcements last. It examines their technical specifications, clinical evidence, and availability in India, where import regulations, Class D medical device classification, and specialized rehabilitation infrastructure shape market access.

ReWalk Robotics: From Concept to Clinical Standard

ReWalk's personal exoskeleton line has transitioned from early clinical trials to FDA-cleared and CE-marked commercial deployment. The current generation, ReWalk 6.0 (commercially distributed as ReWalk Personal), utilizes a hybrid actuation system with electric motors at the hip and knee joints, paired with an inertial measurement unit (IMU) and microcontroller for gait phase detection. The device is designed for individuals with spinal cord injury (SCI) and multiple sclerosis (MS), enabling standing, stepping, and limited ambulation with assistive devices.

ReWalk's regulatory milestones include FDA 510(k) clearance for the personal exoskeleton and subsequent CE Marking under the EU MDR framework. The hardware ships as a complete system with a spinal brace, thigh cuffs, calf supports, and a dedicated control unit worn at the waist. Battery life typically supports 4 to 6 hours of intermittent use, depending on gait speed and terrain.

Clinical deployments have expanded through certified rehabilitation centers and specialized home-care programs. Independent clinical studies, including randomized controlled trials published in peer-reviewed journals, have documented improvements in walking speed, endurance, and cardiovascular markers for eligible SCI patients. However, the system requires significant setup time, therapist supervision for initial sessions, and strict patient selection criteria regarding bone density, joint range of motion, and cognitive capacity.

Ekso Bionics: Hospital-Grade Gait Training

Ekso Bionics focuses on the EksoGT, a hospital-deployed gait training exoskeleton designed for neurological rehabilitation. Unlike personal-use systems, the EksoGT is intended for clinical environments where therapists manage weight-bearing, gait patterning, and progression. The device uses a lightweight carbon-fiber frame with electric hip and knee actuators, a spinal column for posture support, and a pelvic girdle that distributes load across the pelvis rather than the lower limbs.

EksoGT achieved FDA 510(k) clearance for use in neurological rehabilitation and has been deployed across thousands of clinical sites in North America and Europe. The platform integrates with standard therapy workstations and includes a footplate system that allows for overground training, treadmill use, and stair climbing in controlled settings. The control system relies on therapist-managed gait initiation and speed modulation, with safety protocols that include emergency stop mechanisms and weight-shift detection.

Clinical evidence for EksoGT draws from multi-center trials and systematic reviews. Research indicates measurable improvements in gait velocity, step symmetry, and lower-extremity strength in stroke and incomplete SCI populations. The device's hospital deployment model has proven scalable, with rehabilitation chains standardizing gait therapy protocols around its capabilities. Long-term sustainability remains a subject of ongoing study, particularly regarding cost-effectiveness compared to conventional therapy and the threshold for functional independence gains.

Cyberdyne HAL: Sensorimotor Feedback and Japanese Regulatory Milestones

Cyberdyne's Hybrid Assistive Limb (HAL) operates on a fundamentally different principle: bioelectricity-based sensorimotor feedback. Instead of relying solely on pre-programmed gait cycles or IMU phase detection, HAL reads surface electromyography (sEMG) signals from the user's residual muscle activity. When the brain attempts to move, the resulting bioelectric signal is detected by electrodes on the skin, triggering actuators to assist the intended motion. This closed-loop architecture aims to reinforce neural pathways through voluntary effort rather than passive movement.

Cyberdyne secured approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for HAL in stroke and SCI rehabilitation, followed by CE Marking under EU MDR Class IIa/III classifications. The system ships in two primary configurations: HAL (Leg) for lower-limb gait training and HAL (Arm) for upper-limb rehabilitation. The Leg variant includes a pelvic sensor, thigh and calf supports, and a waist-mounted control unit that processes sEMG signals in real time.

Clinical deployments in Japan and Europe have focused on neurorehabilitation centers and university hospitals. Independent studies have reported improvements in muscle activation patterns, walking symmetry, and voluntary control in stroke patients. The sensorimotor feedback approach distinguishes HAL from position-controlled exoskeletons, though it introduces complexities in electrode placement, signal noise, and patient selection. Devices requiring consistent sEMG signals may not be suitable for patients with severe muscle atrophy or complete denervation.

Clinical Evidence: What the Peer-Reviewed Literature Shows

Rehab exoskeleton outcomes must be evaluated against systematic reviews and randomized controlled trials rather than manufacturer white papers. The evidence base reveals consistent but nuanced results:

India Market Accessibility and Pricing

In India, rehab exoskeletons are classified as Class C or D medical devices under the CDSCO Medical Devices Rules, requiring stringent import licensing, clinical evaluation documentation, and post-market surveillance compliance. No domestic manufacturing of commercial rehab exoskeletons exists as of 2024. All units are imported through authorized medical equipment distributors or direct hospital procurement channels.

Approximate landed costs in India reflect base pricing, import duties, GST, and clinical onboarding fees:

Pilot deployments have occurred at select centers including AIIMS New Delhi, CMC Vellore, and private rehabilitation chains such as Apollo Hospitals and Narayana Health. These programs focus on stroke, incomplete SCI, and post-orthopedic surgery gait training. Reimbursement through state health schemes remains limited, with most patients accessing treatment through private insurance or out-of-pocket funding. Local distributor networks are expanding, but regulatory clearance timelines and clinical validation requirements continue to shape market entry.

References

FDA 510(k) Database. ReWalk Robotics Personal Exoskeleton. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm

FDA 510(k) Database. Ekso Bionics EksoGT. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm

Cyberdyne Inc. Official Product Specifications and Regulatory Approvals. https://www.cyberdy.jp/en/hal/

Wu et al. (2023). Exoskeleton-assisted gait training in incomplete spinal cord injury: a systematic review and meta-analysis. Spinal Cord, 61(4), 289-301. https://www.nature.com/sc/

Colombo et al. (2021). Clinical efficacy of the EksoGT exoskeleton in stroke rehabilitation. Archives of Physical Medicine and Rehabilitation, 102(8), 1542-1550. https://www.archives-pmr.org/

CDSCO. Medical Devices Rules, 2017 (Class C/D Classification). https://cdsco.gov.in/opencms/resources/UploadUploadCDSCOWeb/2017/Upload%20Medical%20Device%20Rules%202017.pdf

Ministry of Health, Labour and Welfare Japan. PMDA Approval Notice for HAL System. https://www.pmda.go.jp/english/

✓ Key takeaways

  • •Hands-on view of Rehab Exoskeletons: Shipping Hardware, Clinical Evidence, and the Indian Market inside our Rehab Exoskeletons library.
  • •Shipping hardware beats rendered concepts - we grade claims against what you can actually buy or deploy today.
  • •India pricing and availability are tracked alongside global launch details where they matter.

References

  1. FDA 510(k) Database - ReWalk Robotics
  2. FDA 510(k) Database - Ekso Bionics
  3. Cyberdyne Inc. - HAL Product Specifications
  4. Wu et al. (2023) - Exoskeleton-assisted gait training systematic review
  5. Colombo et al. (2021) - EksoGT stroke rehabilitation study
  6. CDSCO - Medical Devices Rules 2017
  7. PMDA Japan - HAL System Approval
Editorial note Robot specs, release timelines and India prices shift quickly. We update articles as new information lands, but always confirm directly with the manufacturer or an authorised importer before making a purchase decision.

Get the weekly RobotWale brief

One short email a week. New humanoid launches, prices that actually matter in India, hands-on reviews and the research papers worth reading. No hype. No sponsored fluff.

Free. Unsubscribe any time. We will never share your email.